Management

CEO
Vuong Trieu, PhD
Founder of IgDraSol and Biomiga Diagnostics. Led the development of Abraxane, nab-docetaxel, nab-rapamycin, nab- 17-AAG, nab-IDN5404. Repositioned Genexol-PM from Korea into a viable product for US market as Abraxane equivalent and as drug-device combination. Conducted a successful EOP2 meeting within 7 months of acquiring the asset.
Abraxis Biosciences,(ABI), Celgene, AME (Eli Lilly), Genetic Therapy Inc. (Novartis), IgDraSol, Sorrento Therapeutics
CBO
Chulho Park, PhD
Recognized pharmaceutical leader in Korea with strong business development background. Leader in the field of mAb engineering. CEO and Founder of MabPrex. Led the pharmaceutical development of therapeutic antibodies as well as small molecule drugs. President of Pharmaceutical Development at Igdrasol. Led the CMC deveopment at IgDraSol bringing manufacturing of the drug product to US FDA standard.
Eli Lilly, AME, aTyr, MabPrex, IgDraSol
CSO
Larn Hwang, PhD
Drug developer veteran with broad expertise in drug discovery and biomarker development. Key strength on drug discovery/development, clinical and regulatory operations. Led the team through a successful EOP2 meeting and FPI within 4 months of protocol. Founder of IgDraSol and Biomiga Diagnostics.
J&J, ABI, Celgene, IgDraSol, Biomiga Diagnostics, Sorrento Therapeutics
CLO
Pyng Soon ESQ., CPA
Counsel to Murchison & Cumming, LLP previously, in the areas of international law, business litigation and business transactions. Mr. Soon has played an integral part in many business and civil litigation cases . He also has experience with SEC matters including APO/PIPE. A licensed CPA, Mr. Soon previously served as a senior tax consultant at one of the world's "Big 4" accounting companies and corporate controller for a $700 million sales corporation.